CA2307853A1 - Diaryl-5-alkyl-5-methyl-2(5h)-furanones utilisees en tant qu'inhibiteurs selectifs de cyclo-oxygenase-2 - Google Patents

Diaryl-5-alkyl-5-methyl-2(5h)-furanones utilisees en tant qu'inhibiteurs selectifs de cyclo-oxygenase-2 Download PDF

Info

Publication number
CA2307853A1
CA2307853A1 CA002307853A CA2307853A CA2307853A1 CA 2307853 A1 CA2307853 A1 CA 2307853A1 CA 002307853 A CA002307853 A CA 002307853A CA 2307853 A CA2307853 A CA 2307853A CA 2307853 A1 CA2307853 A1 CA 2307853A1
Authority
CA
Canada
Prior art keywords
phenyl
furanone
methyl
dihydro
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307853A
Other languages
English (en)
Inventor
Zhoayin Wang
Serge Leger
Erich Grimm
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9806430.6A external-priority patent/GB9806430D0/en
Application filed by Individual filed Critical Individual
Publication of CA2307853A1 publication Critical patent/CA2307853A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention se rapporte à des composés représentés par la formule (I) ainsi qu'à un procédé de traitement des maladies liées à la présence de cyclo-oxygénase-2 (COX-2), consistant à administrer à un patient justiciable d'un tel traitement une quantité thérapeutiquement efficace et non toxique du composé représenté par la formule (I), par exemple une (5R)-3-(3,4-difluorophényl)-5-éthyl-5-méthyl-4-[4-(méthylsulfonyl)phényl]-2,5-dihydro-2-furanone.
CA002307853A 1997-10-30 1998-10-27 Diaryl-5-alkyl-5-methyl-2(5h)-furanones utilisees en tant qu'inhibiteurs selectifs de cyclo-oxygenase-2 Abandoned CA2307853A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6440997P 1997-10-30 1997-10-30
US60/064,409 1997-10-30
GB9806430.6 1998-03-25
GBGB9806430.6A GB9806430D0 (en) 1998-03-25 1998-03-25 Diaryl-5-alkyl-5-methyl-2(5H)-furanones as selective cyclooxygenase-2 inhibitors
PCT/CA1998/000998 WO1999023087A1 (fr) 1997-10-30 1998-10-27 Diaryl-5-alkyl-5-methyl-2(5h)-furanones utilisees en tant qu'inhibiteurs selectifs de cyclo-oxygenase-2

Publications (1)

Publication Number Publication Date
CA2307853A1 true CA2307853A1 (fr) 1999-05-14

Family

ID=26313357

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307853A Abandoned CA2307853A1 (fr) 1997-10-30 1998-10-27 Diaryl-5-alkyl-5-methyl-2(5h)-furanones utilisees en tant qu'inhibiteurs selectifs de cyclo-oxygenase-2

Country Status (5)

Country Link
EP (1) EP1028951A1 (fr)
JP (1) JP2001521932A (fr)
AU (1) AU741790B2 (fr)
CA (1) CA2307853A1 (fr)
WO (1) WO1999023087A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
KR20000066223A (ko) * 1999-04-14 2000-11-15 서경배 디아릴-3(2ｈ)퓨라논 유도체 및 이를 함유하는 시클로옥시게네이즈-2 저해제 조성물
EA008242B1 (ru) 1999-12-08 2007-04-27 Фармация Корпорейшн Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний
CA2401697A1 (fr) 2000-03-03 2001-09-07 Pfizer Products Inc. Derives d'ether de pyrazole utilises comme agents anti-inflammatoires/analgesiques
AU2001258677A1 (en) * 2000-05-22 2001-12-03 Dr. Reddy's Research Foundation Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
NZ524252A (en) 2000-07-20 2004-03-26 Lauras As Cox-2 inhibitors for treating HIV and AIDS
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
CA3209491A1 (fr) 2021-03-15 2022-09-22 Saul Yedgar Dipalmitoyl-phosphatidyl-ethanol-amine conjuguee a l'acide hyaluronique en combinaison avec des medicaments anti-inflammatoires non steroidiens (ains) pour traiter ou soulager des maladies inflammatoire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
UA57002C2 (uk) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування

Also Published As

Publication number Publication date
AU9618098A (en) 1999-05-24
JP2001521932A (ja) 2001-11-13
AU741790B2 (en) 2001-12-06
WO1999023087A1 (fr) 1999-05-14
EP1028951A1 (fr) 2000-08-23

Similar Documents

Publication Publication Date Title
EP0828724B1 (fr) Diaryl-5-oxygene-2-(5h)-furanones utiles comme inhibiteurs de cox-2
US6133292A (en) Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
US5698584A (en) 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors
EP0912518B1 (fr) Pyridines substituees en tant qu'inhibiteurs selectifs de la cyclo-oxygenase-2
CA2176974C (fr) Heterocycles phenyliques, inhibiteurs de la cyclooxygenase-2
US5925631A (en) Alkylated styrenes as prodrugs to COX-2 inhibitors
US6057319A (en) 3,4-Diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
EP1012142B1 (fr) Pyridines 2,3,5-trisubstituees utilisees comme inhibiteurs de la cyclo-oxygenase 2
CA2234642C (fr) 3,4-diaryle-2-hydroxy-2,5-dihydrofurans utilises comme promedicaments pour inhibiteurs de cox-2
US5981576A (en) (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
EP0975604B1 (fr) Pyridazinones utilises comme inhibiteurs de cyclo-oxygenase-2
US6046217A (en) 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
US6465509B2 (en) Pyrones as inhibitors of cyclooxygenase-2
AU741790B2 (en) Diaryl-5-alkyl-5-methyl-2(5H)-furanones as selective cyclooxygenase-2 inhibitors
AU2001268881A1 (en) Pyrones as inhibitors of cyclooxygenase-2
EP0970067B1 (fr) (methylsufonyl)phenyl-2-(5h)-furanones a liaison oxygene, utilisees comme inhibiteurs de cyclo-oxygenase-2
US6071954A (en) (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
AU6818298A (en) Alpha-methylene gamma lactones as selective cyclooxygenase-2 inhibitors
EP1015431B1 (fr) 2-aminopyridines utilisees comme inhibiteurs de la cyclo-oxygenase 2
WO1997028120A1 (fr) Stilbenes de diphenyle utilises en tant que promedicaments d'inhibiteurs de cox-2
US6004960A (en) Pyridazinones as inhibitors of cyclooxygenase-2
US6004950A (en) 2-aminopyridines as inhibitors of cyclooxygenase-2
EP0900201A1 (fr) Pyridinyl-2-cyclopenten-1-ones utilisees comme inhibiteurs de cyclooxygenase selectifs
AU741981B2 (en) (Methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as cox-2 inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead